Avacta Group PLC - developer of diagnostics and cancer therapies - Says that shipment of its AffiDX SARS-CoV-2 antigen lateral flow test has now commenced. The test has been shown by independent clinical evaluation to be 100% sensitive for patient samples with a PCR Ct value below 27 (high viral load), 98.0% sensitive across a much wider range of viral loads and with 99% specificity. The test has also been shown to detect all the major variants of the virus including the delta variant.
Current stock price: 128 pence
Year-to-date change: up 4.9%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Avacta Group (AVCT)